论文部分内容阅读
随着经皮冠状动脉介入术(PCI)技术的发展,含碘对比荆的使用越来越广泛,其安全性也日益受到关注.冠状动脉慢性完全闭塞(chronic total occlusion,CTO)病变约占全部冠状动脉造影阳性病例的1/3,被称为PCI“未被攻破的最后堡垒”.由于CTO病变PCI用时较长,对比裁用量大,由此导致的对比剂相关并发症风险明显高于非CTO病变,一定程度上影响着CTO病变介入治疗的总体效果.因此,对比剂的合理应用是CTO病变介入治疗的重要考量.现通过结合临床、查阅文献,探讨对比剂在CTO病变介入治疗中的注意事项,希望对CTO病变中对比剂的合理使用提供参考.“,”With the development of percutaneous coronary intervention(PCI),the use of iodinated contrast agent has become highly common,and its safety has received increasing attention.Accounting to one third of coronary angiography positive cases,chronic total occlusion (CTO) is referred to as “the last fort that cannot be conquered”.Because CTO-PCI takes time and the dosage of contrast agent is large,it leads to the increased risk of contrast agent related complications significantly higher than non-CTOs and at the same time affects the overall effect of CTO-PCI.Hence,the reasonable application of contrast agent should cause increased attention.According to the combination of clinical experience and references to literature,this paper will discuss the application notice of contrast agent in CTO intervention.Therefore providing some reference for contrast agent reasonably use in CTO intervention.